Pancreatic Cancer Research

ResearcherArmy Medical UniversityActive in the last 2 years

Wei Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4841-8356; OpenAlex author ID A5100431816. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 7

  1. LncRNA VASH1 antisense RNA 1/miR-199a-5p/Programmed Cell Death 4 Axis Regulate Proliferation, Apoptosis, and Cell Cycle in Pancreatic Ductal Adenocarcinoma Pro… Co-author DOI 10.1166/jbn.2024.3834↗
  2. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  3. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  4. LNC00673 suppresses proliferation and metastasis of pancreatic cancer via target miR-504/ HNF1A. Co-author DOI 10.7150/jca.32855↗
  5. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  6. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗
  7. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Co-author DOI 10.1016/j.pan.2014.07.013↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 5 shared papers, 2014–2024 · strength 0.45
  2. Rong Hua · 5 shared papers, 2014–2024 · strength 0.45
  3. Yan‐Miao Huo · 5 shared papers, 2014–2024 · strength 0.45
  4. Jian‐Yu Yang · 4 shared papers, 2016–2024 · strength 0.41
  5. Junfeng Zhang · 4 shared papers, 2014–2024 · strength 0.39
  6. Xing Huang · 1 shared paper, 2024 · strength 0.31
  7. Xiao Tan · 1 shared paper, 2024 · strength 0.31
  8. Bole Tian · 1 shared paper, 2024 · strength 0.31
  9. Xueliang Fu · 3 shared papers, 2016–2021 · strength 0.23
  10. Minwei Yang · 3 shared papers, 2016–2021 · strength 0.23
  11. Yu-Heng Zhu · 1 shared paper, 2024 · strength 0.18
  12. Zong‐Hao Duan · 1 shared paper, 2024 · strength 0.18
  13. Qin-Yuan Jia · 1 shared paper, 2024 · strength 0.18
  14. Jia-Hao Zheng · 1 shared paper, 2024 · strength 0.18
  15. Yifan Yin · 1 shared paper, 2024 · strength 0.18
  16. Hong‐Fei Yao · 1 shared paper, 2024 · strength 0.18
  17. Leida Zhang · 1 shared paper, 2020 · strength 0.13
  18. Ping Bie · 1 shared paper, 2020 · strength 0.13
  19. Yi Gong · 1 shared paper, 2020 · strength 0.13
  20. Ping Lu · 1 shared paper, 2021 · strength 0.12
  21. Dejun Liu · 1 shared paper, 2021 · strength 0.12
  22. Shu‐Heng Jiang · 1 shared paper, 2021 · strength 0.12
  23. Jie Hong · 2 shared papers, 2014–2016 · strength 0.09
  24. Junfeng Zhang · 1 shared paper, 2016 · strength 0.06
  25. Dejun Liu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.